Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

McGrail, DJ; Pilié, PG; Rashid, NU; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, AB; Ueno, NT; Ferrarotto, R; Chang, JT; Lin, SY

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

journal contribution

posted on 2024-06-13, 14:35 authored by DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, AB Heimberger, NT Ueno, R Ferrarotto, JT Chang, SY Lin

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

History

Journal

Annals of Oncology

Volume

32

Pagination

1194-1197

Location

England

Publisher DOI

https://doi.org/10.1016/j.annonc.2021.06.017

ISSN

0923-7534

eISSN

1569-8041

Language

en

Author URL

https://www.ncbi.nlm.nih.gov/pubmed/34166757

Publication classification

C4 Letter or note

Issue

9

Publisher

Elsevier BV

Usage metrics

Keywords

Antibodies, Monoclonal, Humanized Humans Neoplasms Prevalence 3211 Oncology and carcinogenesis 3201 Cardiovascular medicine and haematology

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

History

Journal

Volume

Pagination

Location

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports